Literature DB >> 18271884

Nifedipine concentration in maternal and umbilical cord blood after nifedipine gastrointestinal therapeutic system for tocolysis.

A-L Silberschmidt1, W N Kühn-Velten, A-M Juon, R Zimmermann, U von Mandach.   

Abstract

OBJECTIVE: To determine nifedipine concentrations in maternal plasma at steady state, and maternal and umbilical cord plasma at delivery, after tocolysis with nifedipine gastrointestinal therapeutic system (GITS) tablets.
DESIGN: Prospective clinical pharmacokinetic study.
SETTING: Department of Obstetrics at the Zurich University Hospital. POPULATION: Pregnant women treated for threatened preterm labour.
METHODS: GITS dosage titrated to clinical response (30-150 mg/day). Nifedipine concentrations by high-performance liquid chromatography and turbo ion spray tandem mass spectrometry. MAIN OUTCOME MEASURES: Steady-state nifedipine concentrations in maternal blood and nifedipine concentrations in maternal and corresponding umbilical cord blood at delivery.
RESULTS: Steady-state nifedipine concentrations (micrograms/l, mean +/- SE) were 54 +/- 6 (all doses, n = 31), 38 +/- 8 (60 mg/day, n = 13), and 92 +/- 12 (150 mg/day, n = 7) (P < 0.002). Umbilical cord and maternal concentrations both declined in a ln-linear regression with elimination half-lives of 20.4 and 17.4 hours. Linear regression showed a correlation between umbilical and maternal concentrations of 0.77 +/- 0.1 (n = 21, mean +/- SE).
CONCLUSIONS: Steady-state plasma nifedipine concentrations after repeated dosing with nifedipine GITS 30-150 mg/day in pregnant women with preterm labour do not exceed 100 micrograms/l; fetal levels are 77% of maternal levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18271884     DOI: 10.1111/j.1471-0528.2007.01630.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  5 in total

1.  Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women.

Authors:  Gabriela Campos de Oliveira Filgueira; Osmany Alberto Silva Filgueira; Daniela Miarelli Carvalho; Maria Paula Marques; Elaine Christine Dantas Moisés; Geraldo Duarte; Vera Lucia Lanchote; Ricardo Carvalho Cavalli
Journal:  Br J Clin Pharmacol       Date:  2017-01-29       Impact factor: 4.335

Review 2.  The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions.

Authors:  Ian R Mulrenin; Julian E Garcia; Muluneh M Fashe; Matthew Shane Loop; Melissa A Daubert; Rachel Peragallo Urrutia; Craig R Lee
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-11       Impact factor: 4.481

Review 3.  Effect of pregnancy on the pharmacokinetics of antihypertensive drugs.

Authors:  Gail D Anderson; Darcy B Carr
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 4.  Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review.

Authors:  Dylan van de Vusse; Paola Mian; Sam Schoenmakers; Robert B Flint; Willy Visser; Karel Allegaert; Jorie Versmissen
Journal:  Eur J Clin Pharmacol       Date:  2022-09-15       Impact factor: 3.064

5.  Maternal hypotension during fetoscopic surgery: incidence and its impact on fetal survival outcomes.

Authors:  Pornswan Ngamprasertwong; Mounira Habli; Anne Boat; Foong Yen Lim; Hope Esslinger; Lili Ding; Senthilkumar Sadhasivam
Journal:  ScientificWorldJournal       Date:  2013-10-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.